The sNDA for acquired hyothalamic obesity is supported by data from the randomized, double-blind, placebo-controlled phase 3 TRANSCEND trial.

HealthDay News — For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood pressure (SBP) target (<120 mm Hg) seems cost-effective at ...

Significant decrease seen in serum levels of vascular endothelial growth factor and interleukin-1 receptor antagonist at 12 months.

Authors say findings support addressing smoking cessation during substance use treatment. HealthDay News — Quitting smoking is associated with recovery from substance use disorder (SUD), according to ...

Health systems can use electronic health record data to target households rather than just individuals, authors say.

Signs and symptoms linked with withdrawal are relatively consistent in pediatric population; can be seen after five or more days of opioids ...

The Signos Glucose Monitoring System is a mobile device application that receives data from an OTC integrated continuous glucose monitor, the Dexcom Stelo Biosenor.

HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online August 14 in ...

Improved functional, survival outcomes seen with risdiplam treatment before development of clinical signs or symptoms.

Cassandra Pingali, MPH, from the CDC in Atlanta, and colleagues analyzed data from the 2024 National Immunization Survey-Teen to examine national, state, and selected local area vaccination coverage ...

The new AAP schedule provides guidance for routine immunization against 18 diseases, including updates for RSV, influenza, and COVID-19 immunization.

Semaglutide linked to increased risk of nonarteritic anterior ischemic optic neuropathy, but evidence remains insufficient to establish definitive conclusion.